Trial · NCT02439320
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Who Are Headache Pain Free | 2 hours post dose | The percentage of participants defined as mild, moderate, or severe headache pain becoming none. |
| Primary | Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free | 2 hours post dose | The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent. |
| Secondary | Percentage of Participants Who Have Headache Relief After First Dose | 2 hours post dose | The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none. |
| Secondary | Percentage of Participants With Headache Recurrence | From 2 hours post dose up to 48 hours | Participants who received study drug and which became pain free at 2 hours post-dose and worsened again up to 48 hours post-dose. |
| Secondary | Percentage of Participants Who Used Rescue Medication | 2 hours post dose | Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free). |
| Secondary | Percentage of Participants Who Used Rescue Medication | Anytime between 2-24 hours post dose | Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free). |
| Secondary | Percentage of Participants Who Used Rescue Medication | Anytime 24-48 hours post dose | Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free). |
| Secondary | Percentage of Participants Nausea Free | 2 hours post dose | The percentage of participants without nausea. |
| Secondary | Percentage of Participants Phonophobia Free | 2 hours post dose | The percentage of participants without phonophobia. |
| Secondary | Percentage of Participants Photophobia Free | 2 hours post dose | The percentage of participants without photophobia. |
| Secondary | Participants With Serious Adverse Events (SAE) | Baseline up to 11 weeks | Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section |
| Other | Percentage of Participants With Resource Utilization | 6 months prior to enrolling in study to end of study (Up to 11 Weeks) within 7 days of treating a single migraine attack | Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02439320/registered